



Press release

Contact:

Jeff Bork, President and CEO

Tel: +46 734 22 16 60

Dave Patteson, President Discovery Chemistry

Tel: +1 434 979 2319

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Biotage receives largest committed order in history

7 June, 2004

Biotage received the company's largest committed order in history to one of the largest pharmaceutical companies in the world. The order value represents approximately 1.5 MUSD. The order comprises a minimum of 53 instruments including the new separation and purification systems Sp1 and Sp4 as well as the newly launched Initiator for microwave synthesis. The systems are to be delivered during the summer 2004.

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. Customers include the worlds top 30 pharmaceutical companies, 20 largest biotech companies and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, Japan and several European countries. Biotage has approx. 250 employees and had pro forma sales of 362 MSEK in 2003. Biotage is listed on the Stockholm stock exchange. Website: www.biotage.com

Certain statements in this press release are forward-looking. These may be identified by the use of forward looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotages current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotages products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.